CompletedPhase 1NCT03922061

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

Studying Poliomyelitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Vermont
Principal Investigator
Kelly Cowan, M.D.
University of Vermont
Intervention
dmLT(biological)
Enrollment
29 target
Eligibility
18-45 years · All sexes
Timeline
20192020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03922061 on ClinicalTrials.gov

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

See all trials for Poliomyelitis

← Back to all trials